 |
|
Plasma D-Dimers in the Diagnosis of Venous Thromboembolism
James Kelly, BSC, MRCP;
Anthony Rudd, FRCP;
Roger R. Lewis, MD, FRCP;
Beverley J. Hunt, MD, FRCP, FRCPath
Arch Intern Med. 2002;162:747-756.
ABSTRACT
| |
Clinical suspicion for venous thromboembolism (VTE) mandates objective
testing to confirm or exclude the diagnosis. However, current imaging modalities
are imperfect because of a small but important risk of complications with
invasive techniques or limited sensitivity with noninvasive ones. A diagnostic
tool for VTE is needed that is noninvasive and highly accurate, allowing immediate
treatment decisions to be made in most cases. Plasma D-dimers (D-ds), specific
cross-linked fibrin derivatives, partially fulfill these criteria in that
they are sensitive markers for thrombosis but lack specificity. They therefore
cannot be used to make a positive diagnosis of VTE; however, they generally
have high negative predictive value and are useful as an exclusionary test,
a potentially important role given that VTE is eventually ruled out in most
patients investigated. Clinical management studies are clarifying the role
of D-ds in the diagnostic paradigm of VTE: negative ultrasound and D-d findings
obviate the need for serial imaging in suspected deep vein thrombosis, and
anticoagulant therapy can be safely withheld in patients with non–high
clinical suspicion for pulmonary embolism and non–high probability ventilation
perfusion scan if D-d test results are negative. More recently, the combination
of a negative SimpliRED (AGEN Biomedical Ltd, Brisbane, Australia) D-d result
and low clinical suspicion derived using a formal scoring system has been
shown to exclude deep vein thrombosis and pulmonary embolism and to obviate
the need for imaging. Several different D-d assays are now available, and
clinicians should be aware of the performance characteristics of the test
used before incorporation into diagnostic algorithms as these will differ
between assays, and the results of clinical management studies cannot necessarily
be safely extrapolated to assays other than those specifically evaluated.
If alternative assays are to be substituted, these should consistently have
been shown to possess equivalent or greater sensitivity.
INTRODUCTION
The incidence of venous thromboembolism (VTE) rises progressively with
age,1-2 with a cumulative event
rate greater than 10% by age 80 years,2 and
is associated with substantial morbidity and mortality in the absence of treatment.3-4 The clinical signs and symptoms are
not sufficiently specific to establish or exclude the diagnosis,5
and objective testing is required in the presence of clinical suspicion to
aid management decisions,6 although all imaging
techniques currently used have clinical or practical limitations.
Contrast venography (CV) and pulmonary angiography remain the gold standard
diagnostic tests for deep vein thrombosis (DVT) and pulmonary embolism (PE),
respectively, but they are invasive and are associated with a small but significant
risk of complications.7 These tests are therefore
no longer widely used as first-line investigations. Noninvasive diagnostic
strategies have been developed, usually using ultrasound, the most accurate
noninvasive test for suspected DVT,8 and ventilation-perfusion
(VQ) scanning for suspected PE. However, VTE can only be diagnosed or excluded
with reasonable confidence using a 1-step process in a few patients. Three
fourths or more of the patients with suspected DVT have negative ultrasound
findings8-9 and require repeated
imaging to identify the further 2% to 6% in whom occlusive proximal DVT becomes
apparent in a week.8, 10 In addition,
70% of patients with suspected PE have a nondiagnostic VQ scan11
(low or intermediate probability) and require further imaging using either
pulmonary angiography or serial noninvasive imaging with ultrasonography to
identify residual proximal DVT, a valid approach in patients with adequate
cardiopulmonary reserve.12-14
Given these shortcomings, a simple but reliable noninvasive test for
VTE is highly desirable and should ideally have a sensitivity and negative
predictive value of 100% as the consequences of nondiagnosis are potentially
life threatening.3-4 Plasma D-dimers
(D-ds) have proved to be the most useful blood markers of intravascular fibrinolysis15 and are of interest as an adjunctive exclusionary
test in suspected VTE, potentially increasing the number of patients who can
be satisfactorily treated without recourse to a second level of investigation.16 We review D-ds in relation to VTE and their incorporation
into diagnostic strategies.
WHAT ARE D-ds?
Plasma D-ds are generated when the endogenous fibrinolytic system degrades
fibrin, as in VTE, and they consist of 2 identical subunits derived from 2
fibrin molecules. Unlike fibrinogen degradation products, which are derived
from fibrinogen and fibrin, D-ds are a specific cross-linked fibrin derivative.17-18 Because 2% to 3% of plasma fibrinogen
is degraded to fibrin, small amounts are detectable in the plasma of healthy
individuals. The half-life is approximately 8 hours, with plasma clearance
via urinary excretion and the action of the reticuloendothelial system.19
RELATIONSHIP BETWEEN VTE AND D-d LEVELS
D-dimer levels are increased by any condition in which fibrin is formed
and degraded by plasmin19 and are the best
currently available laboratory marker of activation of coagulation.20 D-dimer levels are elevated approximately 8-fold
after VTE compared with controls, with levels falling to approximately one
quarter of the initial value between weeks 1 and 221;
they are significantly higher in patients with extensive proximal DVT than
in those with below-the-knee DVT,22 with peak
levels corresponding to the extent of thrombosis.23
D-dimer levels may be particularly useful in the diagnosis of recurrent DVT,
a subgroup in which conventional imaging has important shortfalls.18 Using direct thrombus magnetic resonance imaging
(MRI), Fraser et al24 recently showed that
D-d levels correlate with clot volume and surface area. Clot surface area
seemed to be the more important determinant, supporting the concept that D-d
generation, release, or both occur primarily at the surface of the thrombus.
After a thrombotic event, D-d levels may normalize within 15 to 20 days20, 23 and are probably most useful for
diagnosis within 11 days of symptom onset.21
Although initiation of heparin calcium therapy causes a sharp decline in levels,
absolute values remain increased compared with those of controls, and the
test remains useful in patients awaiting investigation in whom treatment has
already been started.20, 25-26
OTHER CONDITIONS ASSOCIATED WITH RAISED D-d LEVELS
Levels of D-ds are rarely elevated in healthy individuals22
but may be increased in any condition involving the formation and degradation
of fibrin, such as infections, cancer, surgery, cardiac or renal failure,
acute coronary syndromes, acute nonlacunar stroke, pregnancy, and sickle cell
crises.19, 27-30
Furthermore, many of these conditions are also risk factors for VTE and may
have initial symptoms or signs similar to PE.29
D-dimer levels are therefore less likely to be useful in patients with suspected
VTE and 1 or more of these diagnoses because, for example, increased values
occur in 80% to 90% of those with infections or malignancy.31
MEASUREMENT OF D-d LEVELS
Measurement of D-d levels has been enabled by the development of monoclonal
antibodies that bind to epitopes on D-d fragments that are absent on fibrin,
fibrinogen, and non–cross-linked fragments of fibrin, with detection
of resulting complexes by enzyme-linked immunosorbent assay (ELISA) or agglutination
techniques.29, 32-33
The classic microplate ELISA technique is considered the gold standard,34 but it is not useful as a routine emergency test
as it is suitable for batch analysis and is labor intensive. However, the
recently developed VIDAS test (bioMérieux SA, Marcy-Étoile,
France), which combines the ELISA method with a final detection in fluorescence,35 is fully automated and provides a result within 35
minutes and can therefore be used for single-sample testing.36
Two immunofiltration (membrane ELISA) techniques have also been introduced
that have sensitivities similar to those of conventional ELISAs but higher
specificities: the Instant IA D-d assay (Diagnostica Stago, Inc, Parsippany,
NJ) gives a result in less than 8 minutes but is performed manually and is
qualitative (positive or negative),37 and the
NycoCard D-d assay (Nycomed Pharma AS, Asker, Norway) is semiquantitative
and provides a result in less than 2 minutes.37-38
Other techniques involve agglutination of latex beads or red blood cells
and give a qualitative or semiquantitative result within a few minutes. For
example, the SimpliRED test (AGEN Biomedical Ltd, Brisbane, Australia) is
a red blood cell agglutination assay designed for use with fresh capillary
or venous whole blood. It provides a result in less than 5 minutes and is
therefore suitable for near-patient testing.39
More recently, immunoturbidimetric techniques have been developed that allow
a quantitative estimation and represent a second generation in latex agglutination
technology (eg, TinaQuant assay [Roche Diagnostics, F. Hoffmann-La Roche Ltd,
Basel, Switzerland], Liatest assay [Diagnostica Stago, Inc], and MDA D-d [Organon
Teknika B.V., Boxtel, the Netherlands]). Immunofiltration and immunoturbidimetric
techniques may therefore combine the advantageous properties of the ELISA
with the speed and simplicity of the latex tests. The properties of the main
D-d detection techniques are given in Table
1.
|
|
|
|
Table 1. Characteristics of the Different Classes of D-Dimer Detection
Techniques*
|
|
|
ACCURACY OF TECHNIQUES
Pooled data from 20 studies of more than 2000 outpatients with clinically
suspected VTE using 3 different classic microplate ELISA assays (Dimertest
[American Diagnostica Inc, Greenwich, Conn], Asserachrom Ddi [Diagnostica
Stago, Inc], and Fibrinostika FbDP [Organon Teknika B.V.]) have shown a diagnostic
sensitivity of 97% at a cutoff value of 500 ng/mL,40
with false-negatives presumably explained on the basis of a small thrombus
mass (sensitivity may be lower in patients with isolated below-the-knee DVT22, 41), a long time lag between thrombus
formation and D-d testing,20 and, possibly,
an impaired pathophysiological fibrinolytic response in the occasional patient.42 Specificity in these studies was approximately 35%
to 45%, and D-d levels are currently regarded as useful only as exclusionary
tests for VTE and are less useful in inpatient populations because of lower
specificity consequent on comorbidity.31 More
recent data21, 36-38,40-41,43-53
also show high sensitivities for the 3 novel rapid ELISA-based assays; indeed,
several studies36, 41, 43-46
evaluating the VIDAS assay have reported a sensitivity of 100%.
Whereas conventional latex agglutination assays are not regarded as
sufficiently sensitive to be of clinical value,40, 54-55
second-generation kits using either whole blood agglutination (SimpliRED)
or immunoturbidimetric techniques (eg, TinaQuant, Liatest, and MDA D-d) have
emerged with higher sensitivities and are clinically useful.41, 55-61
Van der Graaf et al41 recently assessed
the diagnostic performance of 10 novel rapid tests based on ELISA or latex
agglutination technology and 3 conventional ELISAs in 99 outpatients with
suspected DVT who underwent CV (Table 2). Correlation between different assays is poor,20, 54
and it is not currently possible to standardize D-d results from different
assays, making it difficult to extrapolate results from one setting to another.
Also, important interobserver variation may occur with semiquantitative tests.36 Studies58, 62-63
have also shown that combining an additional variable, such as a clinical
probability assessment, respiratory rate, arterial blood gas estimation, or
measurement of alveolar dead space, augments the negative predictive value
of a normal D-d value. For example, in a study62
of patients undergoing evaluation for suspected PE, the combination of a negative
SimpliRED assay result and a PaO2 greater than 10.7 kPa had a negative
predictive value of 100%.
|
|
|
|
Table 2. Performance Characteristics of 13 D-Dimer (D-d) Assays in
Suspected Deep Vein Thrombosis*
|
|
|
The VIDAS and SimpliRED assays are the most extensively studied and
widely used in the diagnosis of VTE. Pooled data indicate that although the
VIDAS assay is the more sensitive of the two (90%-100% [generally 98%-100%]),
specificity (5%-55% [generally, 40%]) is relatively poor so that a normal
result has high negative predictive value but occurs in a small proportion
of patients, limiting its diagnostic utility (only data from studies using
a threshold of 500 ng/mL were included).36, 41, 43-53
By contrast, the SimpliRED assay is somewhat less sensitive (61%-100% [generally,
85%]) but more specific (20%-94% [generally, 70%]) so that the negative predictive
value is lower but the test is likely to be diagnostically useful in a greater
proportion of patients.41, 43, 56, 59-60,64-71
The utility of these two tests in clinical management studies are reviewed
herein. Note that specificity of assays vary depending on the population studied
and will be highest in outpatient populations with a low prevalence of comorbidity.
D-d LEVELS IN THE ELDERLY
D-dimer levels increase linearly with age, particularly in the presence
of coexisting functional impairment,72 because
of a combination of factors, including reduced renal clearance, increased
levels of plasma fibrinogen, and the presence of occult disease.19, 73
In one study19 of healthy individuals, average
levels in the highest age quartile (71-90 years) were approximately 4 times
greater than those in the lowest quartile (11-30 years), hence specificity
and therefore diagnostic utility for VTE is lower in older patients (Table 347, 74-75),
although a negative result retains the same clinical value as in younger patients.47, 72, 74-75 In
one study53 evaluating the optimal discriminatory
threshold of the VIDAS assay in elderly inpatients (average age, 86 years)
with suspected DVT, specificity improved at a cutoff value of 750 ng/mL compared
with 500 ng/mL without a decrease in sensitivity, but it was still poor at
only 20%.
|
|
|
|
Table 3. Performance Characteristics of the Asserachrom Ddi ELISA (Diagnostica
Stago, Inc, Parsippany, NJ) in Different Age Strata at a Cutoff Value of 500
ng/mL in 671 Outpatients Investigated for Suspected Pulmonary Embolism*
|
|
|
CAN D-d LEVELS EVER BE USED TO MAKE A POSITIVE DIAGNOSIS OF VTE?
The positive predictive value for VTE rises as D-d levels increase progressively
above the diagnostic threshold,76 and in a
study74 evaluating 671 outpatients with suspected
PE, the specificity of D-d (Asserachrom Ddi ELISA) was 93% when levels exceeded
4000 ng/mL. This raises the possibility that, depending on the pretest probability,
in certain situations a high D-d level might be sufficient grounds to initiate
treatment.74, 77 However, this
issue requires further study and, in the absence of further data, D-d levels
should be used in an exclusionary capacity only at this stage.
MANAGEMENT STUDIES OF D-d IN SUSPECTED VTE
Data demonstrating the high sensitivity of certain D-d assays for the
diagnosis of symptomatic VTE under the optimal conditions of performance studies
suggest a putative role as an exclusionary test. However, outcome studies
demonstrating that treatment can be safely withheld in suspected VTE using
diagnostic approaches incorporating D-d assays under routine conditions are
required, as similar performance cannot be assumed in the less predictable
domain of clinical practice, and even a small margin of error may not be acceptable
with a potentially lethal disease.78 For example,
previous studies have demonstrated that outcome is excellent when treatment
is withheld in suspected DVT on the basis of negative CV79
or serial ultrasound8 findings and in suspected
PE with negative pulmonary angiographic findings80
or normal VQ scintigraphy results.81 Without
similar data, routine clinical use of D-d assays would be premature and could
not be recommended.77
Several management studies have now evaluated D-ds in diagnostic algorithms
for VTE incorporating noninvasive imaging55
and/or information from an a priori clinical probability assessment, the complimentary
role of which in diagnosis has been previously demonstrated.82-85
Bernardi et al86 investigated 946 outpatients
with suspected DVT. Treatment was withheld in patients with negative initial
ultrasound findings and normal D-d levels (Instant IA ELISA: <500 ng/mL
regarded as normal) and the risk of VTE was less than 0.2% at 3 months in
this subgroup. D-dimer results were negative in almost 90% of patients with
negative initial ultrasound findings so that management decisions could be
made in most patients the day of presentation. In a similar study, Kraaijenhagen
et al87 also found that the combination of
negative initial ultrasound findings and normal D-d levels (SimpliRED assay)
in 552 outpatients with suspected DVT was associated with a risk of clinically
apparent VTE of only 0.4% at 3 months in the absence of treatment. The results
of these 2 studies show that serial testing is obviated in the presence of
normal D-d levels, and a recent decision analysis model has shown that this
strategy is likely to be cost-effective.88
In a study by de Groot et al59 evaluating
245 patients for suspected PE, anticoagulant therapy was withheld in the presence
of a nondiagnostic VQ scan, non–high clinical probability, and negative
SimpliRED test results. Only 1 patient (1.5%) in this subgroup experienced
a possible VTE event at 3-month follow-up, an incidence similar to that in
those with normal VQ scan findings, suggesting that this approach was safe.
Similarly, Perrier et al89 evaluated a diagnostic
protocol for PE in 308 patients combining clinical probability, D-d assay
(Asserachrom Ddi ELISA), and ultrasonography in patients with nondiagnostic
VQ scans, with pulmonary angiography reserved for cases in which the noninvasive
workup was inconclusive. Treatment was withheld in 53 patients with nondiagnostic
VQ scans and intermediate clinical probability of PE in whom D-d levels were
less than 500 ng/mL, none of whom developed VTE during the following 6 months.
An additional 363 patients were subsequently recruited, including another
74 with an intermediate clinical probability of PE, nondiagnostic VQ scans,
and negative D-d test results. Again, no cases of VTE occurred in this subgroup
during another 3 months of follow-up.74
Three trials have assessed the safety of obviating imaging in patients
with suspected VTE on the basis of D-d level alone or in combination with
a clinical probability assessment. Perrier et al90
evaluated a noninvasive diagnostic algorithm in 918 patients with suspected
DVT or PE using D-d estimation (VIDAS assay) as the first step. Levels were
less than 500 ng/mL in 159 patients (36%) with suspected PE. These patients
were not investigated further, irrespective of clinical suspicion, and none
developed VTE during the next 3 months. Patients with elevated D-d levels
underwent VQ scanning or ultrasonography, whereas those with suspected DVT
underwent US irrespective of D-d levels. By incorporating a clinical probability
assessment, noninvasive diagnosis was possible in 94% of the entire cohort,
and the risk of VTE at 3 months in those not given anticoagulants using this
algorithm was 1.8%; only 2 of the 12 patients in this subgroup had normal
D-d levels at presentation.
Kearon et al91 evaluated 445 outpatients
with a suspected first episode of DVT who underwent a standardized assessment
of clinical probability (Table 483) and D-d assay (SimpliRED); 40% had a low clinical
probability for DVT and negative D-d findings, and this subgroup was not investigated
further. This strategy was safe, with only 1 of 177 patients developing VTE
during the subsequent 3 months, giving a negative predictive value for this
combination of 99.4%. Finally, Wells et al92
evaluated a predominantly noninvasive diagnostic strategy in 930 outpatients
with suspected PE in which the initial step comprised a standard assessment
of pretest clinical probability93 (Table 5) and D-d assay (SimpliRED), as
in the previous study. Those with low suspicion and negative D-d findings
did not undergo further investigation, with all other patients undergoing
VQ scanning. If the VQ scan was nondiagnostic, bilateral, lower-limb ultrasonography
was performed, with further testing guided by the results of the clinical
assessment, D-d assay, and VQ. Forty-seven percent of the entire group were
considered not to have PE on the basis of low suspicion and negative D-d findings,
and only 1 of these 437 patients developed VTE during the next 3 months, giving
a negative predictive value of 99.5% for this combination. The overall frequency
of VTE during follow-up in the cohort in whom PE was thought to have been
initially excluded and in whom the protocol was followed correctly was 0.1%,
and pulmonary angiography was required in only 1% of the total.
|
|
|
|
Table 4. Clinical Probability Score Used in Patients With Suspected
Deep Vein Thrombosis*
|
|
|
|
|
|
|
Table 5. Clinical Probability Score Used in Patients With Suspected
PE*
|
|
|
These studies provide an evidence base for the use of D-d tests in noninvasive
diagnostic algorithms for suspected VTE. In particular, the studies of Kearon
et al91 and Wells et al92
demonstrate that imaging can safely be obviated in up to half of patients
with suspected VTE using a formal clinical probability assessment in combination
with a SimpliRED D-d test, and invasive testing is rarely required in the
remainder. However, 3 caveats should be borne in mind. First, these results
apply to a specific D-d test and method of clinical probability assessment.
Substitution of an alternative assay would be safe only if its sensitivity
equaled or exceeded that of SimpliRED, though diagnostic utility might be
inferior if specificity were lower. Less sensitive assays should not be used.
Second, the overall prevalences of VTE in these cohorts were less than 15%
so that the frequency of thromboses in the low-probability groups was only
1% to 2%. The negative predictive value of a combined low probability and
negative D-d finding will diminish as disease prevalence rises so that the
safety of this approach cannot be assumed if a significantly higher prevalence
of VTE is anticipated. Third, VTE was diagnosed in up to 20% of patients with
a negative D-d result and high clinical suspicion, demonstrating that the
SimpliRED assay cannot be used in isolation and reinforcing the need for a
careful clinical assessment. In contradistinction, exclusion of PE on the
basis of a negative VIDAS assay finding seemed safe in one study.90 Such an approach would not be acceptable unless sensitivity
of the assay used approximated to 100%, although in the absence of further
confirmatory data, it would seem prudent to exercise caution when the results
of D-d testing using a highly sensitive assay and clinical suspicion are at
odds.
D-d AS A SCREENING TEST FOR ASYMPTOMATIC VTE
Screening studies94-95 in
patients at high risk of DVT clearly demonstrate that only a few patients
have local signs or symptoms. However, subclinical DVT is important as fatal
PE may be its initial manifestation,11 and
postthrombotic syndrome is an important sequela, particularly after proximal
thrombosis.96 Although D-d testing alone would
not allow positive diagnosis of DVT, the concept of its use as a screening
tool in populations at high risk of VTE, potentially optimizing use of noninvasive
imaging in a diminished subgroup, is theoretically attractive. The need for
screening is debatable in general surgical and orthopedic patients as increasingly
effective thromboprophylactic strategies are used.97-99
However, a strong case might exist in, for example, patients after stroke97 in whom prophylactic heparin use is no longer routinely
recommended.100
A few studies evaluating the role of D-d testing as a screening tool
have been reported. Harvey et al101 studied
105 nonambulatory stroke rehabilitation patients an average of 25 days after
ictus. Patients were screened with bilateral lower-limb ultrasonography and
D-d (Asserachrom Ddi ELISA) within the same 24 hours. Fourteen DVTs were identified,
and a D-d threshold of 1092 ng/mL had a sensitivity of 100% and a specificity
of 66%. Positive and negative predictive values were 31% and 100%, respectively.
At this threshold, therefore, the D-d test excluded DVT with the same confidence
as a negative ultrasound finding. Overall, this study demonstrated that DVT
could be excluded in 57% of patients by D-d testing alone. These data cannot
be extrapolated to patients in the acute phase of stroke because of potential
confounding by the effect of stroke itself on D-d levels,30
and the evaluation of D-d as a screening tool in this context requires a separate
study.
Bounameaux et al102 performed D-d measurements
(Asserachrom Ddi ELISA) and bilateral CV on postoperative day 8 in 185 patients
who had undergone gastrointestinal tract surgery. Although D-d levels were
increased substantially by surgery, a threshold of 3000 ng/mL had an 89% sensitivity
and a 48% specificity (positive and negative predictive values, 35% and 93%,
respectively) for the diagnosis of DVT.
Roussi et al103 studied D-d (Asserachrom
Ddi ELISA and Liatest) as a screening test for DVT with ultrasonography, CV,
or both in 67 patients with spinal cord injuries and found that DVT could
be excluded using a standard D-d threshold of 500 ng/mL (either technique)
in 31%, obviating ultrasonography in these patients.
Studies evaluating the screening potential of D-d assays in the context
of orthopedic surgery have yielded conflicting results. Crippa et al104 screened 68 patients undergoing elective hip surgery
with serial D-d measurements (LPIA D-d; Mitsubishi Kasei Corp, Tokyo, Japan;
a quantitative automated immunoturbidimetric assay) and CV at day 10. At a
cutoff value of 3500 ng/mL, the assay had a sensitivity of 100% and a specificity
of 32% for DVT (positive and negative predictive values, 40% and 100%, respectively).
Bongard et al105 evaluated 173 patients undergoing
hip surgery (elective and emergency) using a D-d assay (Asserachrom Ddi ELISA)
and ultrasonography on postoperative day 12. At a cutoff value of 2000 ng/mL,
the sensitivity and specificity for proximal DVT were 79% and 36%, respectively.
Whereas the negative predictive value at this threshold was 95%, the positive
predictive value was only 9%, limiting its usefulness. A preoperative D-d
threshold greater than 500 ng/mL had a sensitivity of 93% and a specificity
of 23% for the subsequent development of proximal DVT (negative and positive
predictive values, 96% and 36%, respectively), and preoperative D-d levels
were also predictive of postoperative DVT in a study106
evaluating patients undergoing major abdominal surgery. Although this might
support the concept that increased fibrin turnover identified patients with
a preoperative hypercoagulable state at increased risk of subsequent DVT,107 preoperative D-d measurement did not predict postoperative
DVT in the European Concerted Action on Thrombosis DVT study, the largest
of its kind evaluating the relationship between preoperative hemostatic variables
and subsequent thrombosis in patients undergoing hip arthroplasty.108 Last, Dunn et al109
measured D-d (Dimertest ELISA) in 90 patients after orthopedic surgery undergoing
CV between days 5 and 7. Although D-d levels were significantly higher in
patients with DVT, the degree of overlap was too great for the test to be
discriminatory in individuals, and the SimpliRED D-d assay was not a useful
screening test in another study110 of patients
after orthopedic surgery.
Although D-d assays have not generally proved useful as a screening
modality after orthopedic surgery because of the overwhelming effect of surgery
per se on levels, these studies indicate that in certain subgroups of high-risk
patients, a 2-step screening process involving an initial D-d estimation might
significantly decrease the number of patients requiring imaging, although
in postoperative patients, optimal cutoff values may change with new surgical
techniques and new thromboprophylactic drugs.18
In general, D-d testing may facilitate identification of a subgroup with an
approximately 1 in 3 probability of having DVT on ultrasound screening, which
compares favorably with the 1 in 4 patients with clinically suspected DVT
in whom the diagnosis is confirmed.111 Studies
are required to evaluate the utility of such an approach in improving clinical
end points and its cost-effectiveness.
NEWER IMAGING MODALITIES FOR VTE
Experience is increasing with spiral computed tomography and contrast-enhanced
electron-beam computed tomography for the diagnosis of PE.34, 112-118
Furthermore, MRI seems promising for the evaluation of DVT and PE,34, 113-114,119
particularly direct thrombus MRI, which detects methemoglobin in maturing
clots and provides a positive image of thrombi.120-121
A major advantage of MRI is that it allows evaluation of the lower limbs and
thorax for clots at the same time, potentially facilitating a more titrated
approach to treatment. For example, the presence or absence of residual proximal
DVT in a patient with PE, the major factor determining the risk of PE recurrence
in the absence of treatment,122-125
could affect decisions about the intensity and duration of treatment. Use
of these techniques is likely to increase as technology advances, and invasive
diagnosis of VTE may be completely obviated in the future. However, further
data from prospective management studies in which anticoagulant treatment
is withheld without further testing for VTE on the basis of negative imaging
findings and large, multicenter studies are required to clarify the role of
computed tomography and MRI in the diagnostic paradigm of VTE.7, 112, 125
CONCLUSIONS
During the past decade, D-d assays have evolved from a theoretically
attractive exclusionary test in suspected VTE to one of practical value that
seems to be safe and cost-effective when used within defined diagnostic strategies,
obviating the need for imaging in a significant proportion of patients, minimizing
the need for repeated or invasive investigations in the remainder, and allowing
immediate treatment decisions to be made more frequently. However, many different
assays are now commercially available, and clinicians should appreciate that
these cannot necessarily be used interchangeably and should ensure that they
are familiar with the diagnostic performance of the assay used in their own
institution.
Ongoing studies will continue to define the role of D-ds in diagnosis.
Further research is needed, for example, to evaluate the safety of using highly
sensitive rapid assays, such as VIDAS, as stand-alone tests. In the absence
of an assay that is highly sensitive and specific, studies evaluating a 2-step
approach consisting of an initial clinical probability assessment and D-d
assay using one of the more specific tests (eg, SimpliRED), followed by a
highly sensitive assay in those with a negative result and non–low clinical
suspicion, would be of interest as this approach would combine the merits
of both classes of assay and potentially further reduce the need for imaging.
AUTHOR INFORMATION
Accepted for publication August 27, 2001.
Corresponding author and reprints: James Kelly, BSC, MRCP, SpR in
Elderly Care/GIM, Elderly Care Dept, c/o Alexandra Ward, North Wing, Ninth
Floor, St Thomas' Hospital, Lambeth Palace Road, Lambeth, London SE1 7EH,
England (e-mail: jameskelly{at}northbrookfm.fsnet.co.uk).
From the Specialist Registrar in Elderly Care and GIM (Dr Kelly); Consultant
in Elderly Care and Stroke Medicine (Dr Rudd); Consultant in Elderly Care,
General Internal Medicine, and Stroke Medicine (Dr Lewis); and Consultant
Haematologist (Dr Hunt), St Thomas' Hospital, London, England.
REFERENCES
| |
1. Kniffin WD, Baron JA, Barrett J, Birkmeyer JD, Anderson FA. The epidemiology of diagnosed pulmonary embolism and deep vein thrombosis
in the elderly. Arch Intern Med. 1994;154:861-866.
FREE FULL TEXT
2. Hansson P, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med. 1997;157:1665-1670.
FREE FULL TEXT
3. Byrne JJ. Phlebitis: a study of 748 cases at the Boston City Hospital. N Engl J Med. 1955;253:579-586.
4. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis. 1975;17:259-270.
ISI
| PUBMED
5. NIH Consensus Development: prevention of venous thrombosis and pulmonary
embolism. JAMA. 1986;256:744-749.
FREE FULL TEXT
6. Sasahara AA, Sharma GV, Barsamian EM, Schoolman M, Cella G. Pulmonary thromboembolism: diagnosis and treatment. JAMA. 1983;249:2945-2950.
FREE FULL TEXT
7. American Thoracic Society. The diagnostic approach to acute venous thromboembolism: clinical practice
guideline. Am J Respir Crit Care Med. 1999;160:1043-1066.
FREE FULL TEXT
8. Heijboer H, Buller HR, Lensing AW, Turpie AG, Colly LP, ten Cate JW. A comparison of real-time compression ultrasonography with impedance
plethysmography for the diagnosis of deep vein thrombosis in symptomatic outpatients. N Engl J Med. 1993;329:1365-1369.
FREE FULL TEXT
9. Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with
clinically suspected deep vein thrombosis: prospective cohort study. BMJ. 1998;316:17-20.
FREE FULL TEXT
10. Birdwell BG, Raskob GE, Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients
suspected of having deep venous thrombosis. Ann Intern Med. 1998;128:1-7.
FREE FULL TEXT
11. The Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)
investigators. Value of the ventilation-perfusion scan in acute pulmonary embolism:
results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)
investigators. JAMA. 1990;263:2753-2759.
FREE FULL TEXT
12. Hull RD, Raskob GE, Ginsberg JS, et al. A noninvasive strategy for the treatment of patients with suspected
pulmonary embolism. Arch Intern Med. 1994;154:289-297.
FREE FULL TEXT
13. Dalen JE. When can treatment be withheld in patients with suspected pulmonary
embolism? Arch Intern Med. 1993;153:1415-1418.
FREE FULL TEXT
14. Stein PD, Hull RD, Pineo G. Strategy that includes serial noninvasive leg tests for diagnosis of
thromboembolic disease in patients with suspected acute pulmonary embolism
based on data from PIOPED. Arch Intern Med. 1995;155:2101-2104.
FREE FULL TEXT
15. Hansson PO, Eriksson H, Eriksson E, Jagenburg R, Lukes P, Risberg B. Can laboratory testing improve screening strategies for deep vein thrombosis
at an emergency unit? J Intern Med. 1994;235:143-151.
ISI
| PUBMED
16. Kraaijenhagen RA, Lensing AW, Lijmer JG, et al. Diagnostic strategies for the management of patients with clinically
suspected deep vein thrombosis. Curr Opin Pulm Med. 1997;3:268-274.
PUBMED
17. Kario K, Matsuo T, Kobayashi H. Which factors affect D-dimer levels in the elderly? Thromb Res. 1991;62:501-508.
FULL TEXT
|
ISI
| PUBMED
18. Crippa L, D'Angelo SV, Tomassini L, Rizzi B, D'Alessandro G, D'Angelo A. The utility and cost-effectiveness of D-dimer measurements in the diagnosis
of deep vein thrombosis. Haematologica. 1997;82:446-451.
FREE FULL TEXT
19. Hager K, Platt D. Fibrin degeneration product concentrations (D-dimers) in the course
of ageing. Gerontology. 1995;41:159-165.
20. Sie P. The value of laboratory tests in the diagnosis of venous thromboembolism. Haematologica. 1995;80(suppl):57-60.
21. D'Angelo A, D'Alessandro G, Tomassini L. Evaluation of a new rapid quantitative D-dimer assay in patients with
clinically suspected deep vein thrombosis. Thromb Haemost. 1996;75:412-416.
ISI
| PUBMED
22. Chapman CS, Akhtar N, Campbell S, Miles K, O'Connor J, Mitchell VE. The use of D-dimer assay by enzyme immunoassay and latex agglutination
techniques in the diagnosis of deep vein thrombosis. Clin Lab Haematol. 1990;12:37-42.
ISI
| PUBMED
23. The DVTENOX Study Group. Markers of haemostatic system activation in acute deep venous thrombosis
evolution during the first days of heparin treatment. Thromb Haemost. 1993;70:909-914.
ISI
| PUBMED
24. Fraser DG, Moody AR, Martel A, Morgan P. Determinants of D-dimer level in patients presenting with deep venous
thrombosis: assessment using magnetic resonance thrombus imaging. In: Abstracts from the European Haematology Association 5th Congress;
June 27, 2000; Birmingham, Ala. Abstract 513.
25. Speiser W, Mallek R, Koppensteiner R, et al. D-dimer and TAT measurement in patients with deep venous thrombosis:
utility in diagnosis and judgement of anticoagulant treatment effectiveness. Thromb Haemost. 1990;64:196-201.
ISI
| PUBMED
26. Estivals M, Pelzer H, Sie P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1 + 2, thrombin-antithrombin 3 complexes and D-dimers
in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol. 1991;78:421-424.
ISI
| PUBMED
27. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen related antigens in patients with stable and
unstable coronary disease. N Engl J Med. 1987;317:1361-1365.
ABSTRACT
28. Gustafsson C, Blomback M, Britton M. Coagulation factors and the increased risk of stroke in nonvalvular
atrial fibrillation. Stroke. 1990;21:47-51.
FREE FULL TEXT
29. Becker DM, Philbrick JT, Bachhuber TL, Humphries JE. D-dimer testing and acute venous thromboembolism. Arch Intern Med. 1996;156:939-946.
FREE FULL TEXT
30. Giroud M, Dutrillaux F, Lemesle M, et al. Coagulation abnormalities in lacunar and cortical ischaemic stroke
are quite different. Neurol Res. 1998;20:15-18.
ISI
| PUBMED
31. Raimondi P, Bongard O, de Moerloose P, Reber G, Waldvogel F, Bounameaux H. D-dimer plasma concentration in various clinical conditions: implication
for the use of this test in the diagnostic approach of venous thromboembolism. Thromb Res. 1993;69:125-130.
FULL TEXT
|
ISI
| PUBMED
32. Whitaker AN, Elms MJ, Masci PP, et al. Measurement of cross linked fibrin derivatives in plasma: an immunoassay
using monoclonal antibodies. J Clin Pathol. 1984;37:882-887.
FREE FULL TEXT
33. Elms MJ, Bunce IH, Bundesen PG, et al. Measurement of cross-linked fibrin degradation products: an immunoassay
using monoclonal antibodies. Thromb Haemost. 1983;50:591-594.
ISI
| PUBMED
34. Indik JH, Alpert JS. Detection of pulmonary embolism by D-dimer assay, spiral computed tomography
and magnetic resonance imaging. Prog Cardiovasc Dis. 2000;42:261-272.
FULL TEXT
|
ISI
| PUBMED
35. Pittet JL, de Moerloose P, Reber G, et al. VIDAS D-dimer: fast quantitative ELISA for measuring D-dimer in plasma. Clin Chem. 1996;42:410-415.
FREE FULL TEXT
36. de Moerloose P, Desmarais S, Bounameaux H, et al. Contribution of a new, rapid, individual and quantitative automated
D-dimer ELISA to exclude pulmonary embolism. Thromb Haemost. 1996;75:11-13.
ISI
| PUBMED
37. Scarano L, Bernardi E, Prandoni P, et al. Accuracy of two newly described D-dimer tests in patients with suspected
deep venous thrombosis. Thromb Res. 1997;86:93-99.
FULL TEXT
|
ISI
| PUBMED
38. Dale S, Gogstad GO, Brosstad F, et al. Comparison of three D-dimer assays for the diagnosis of DVT: ELISA,
latex and an immunofiltration assay (NycoCard D-dimer). Thromb Haemost. 1994;71:270-274.
ISI
| PUBMED
39. John MA, Elms MJ, O'Reilly EJ, Rylatt DB, Bundesen PG, Hillyard CJ. The SimpliRED D dimer test: a novel assay for the detection of crosslinked
fibrin degradation products in whole blood. Thromb Res Suppl. 1990;58:273-281.
FULL TEXT
|
ISI
| PUBMED
40. Bounameaux H, de Moerloose P. Plasma measurement of D-dimer as diagnostic aid in suspected venous
thromboembolism: an overview. Thromb Haemost. 1994;71:1-6.
ISI
| PUBMED
41. Van der Graaf F, van den Borne H, van der Kolk M, de Wild PJ, Janssen GW, van Uum SH. Exclusion of deep venous thrombosis with D-dimer testing. Thromb Haemost. 2000;83:191-198.
ISI
| PUBMED
42. Eisenberg PR. Does a negative D-dimer exclude thrombosis? Fibrinolysis. 1993;7:32-35.
43. Janssen MC, Heebels AE, de Metz M, et al. Reliability of five rapid D-dimer assays compared to ELISA in the exclusion
of deep venous thrombosis. Thromb Haemost. 1997;77:262-266.
ISI
| PUBMED
44. Freyburger G, Trillaud H, Labrouche S, et al. D-dimer strategy in thrombosis exclusion. Thromb Haemost. 1998;79:32-37.
ISI
| PUBMED
45. Keeling DM, Wright M, Baker P, Sackett D. D-dimer for the exclusion of venous thromboembolism: comparison of
a new automated latex particle immunoassay (MDA D-dimer) with an established
enzyme-linked fluorescent assay (VIDAS D-dimer). Clin Lab Haematol. 1999;21:359-362.
FULL TEXT
|
ISI
| PUBMED
46. Shitrit D, Heyd J, Raveh D, Rudensky B. Diagnostic value of the D-dimer test in deep vein thrombosis: improved
results by a new assay method and by using discriminating methods. Thromb Res. 2001;102:125-131.
FULL TEXT
|
ISI
| PUBMED
47. Righini M, Goehring C, Bounameaux H, Perrier A. Effects of age on the performance of common diagnostic tests for pulmonary
embolism. Am J Med. 2000;109:357-361.
FULL TEXT
|
ISI
| PUBMED
48. Legnani C, Pancani C, Palareti G, Guazzaloca G, Coccheri S. Contribution of a new rapid, quantitative and automated method for
D-dimer measurement to exclude deep vein thrombosis in symptomatic outpatients. Blood Coagul Fibrinolysis. 1999;10:69-74.
ISI
| PUBMED
49. Bonnin F, Hadjikostova H, Jebrak G, et al. Complementarity of lung scintigraphy and D-dimer test in pulmonary
embolism. Eur J Nucl Med. 1997;24:444-447.
ISI
| PUBMED
50. Legnani C, Pancani C, Palareti G, et al. Comparison of new rapid methods for D-dimer measurement to exclude
deep vein thrombosis in symptomatic outpatients. Blood Coagul Fibrinolysis. 1997;8:296-302.
ISI
| PUBMED
51. Sijens PE, van Ingen HE, van Beek EJ, Berghout A, Oudkerk M. Rapid ELISA assay for plasma D-dimer in the diagnosis of segmental
and subsegmental pulmonary embolism. Thromb Haemost. 2000;84:156-159.
ISI
| PUBMED
52. Elias A, Aptel I, Huc B, et al. D-dimer test and diagnosis of deep vein thrombosis: a comparative study
of 7 assays. Thromb Haemost. 1996;76:518-522.
ISI
| PUBMED
53. Le Blanche AF, Siguret V, Settegrana C, et al. Ruling out acute deep vein thrombosis by ELISA plasma D-dimer assay
versus ultrasound in inpatients more than 70 years old. Angiology. 1999;50:873-882.
54. van Beek EJ, van den Ende B, Berckmans RJ, et al. A comparative analysis of D-dimer assays in patients with clinically
suspected pulmonary embolism. Thromb Haemost. 1993;70:408-413.
ISI
| PUBMED
55. De Moerloose P. D-dimer assays for the exclusion of venous thromboembolism: which test
for which diagnostic strategy? Thromb Haemost. 2000;83:180-181.
ISI
| PUBMED
56. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Application of a novel and rapid whole blood assay for D-dimer inpatients
with clinically suspected pulmonary embolism. Thromb Haemost. 1995;73:35-38.
ISI
| PUBMED
57. Oger E, Leroyer C, Bressollette L, et al. Evaluation of a new, rapid, and quantitative D-dimer test in patients
with suspected pulmonary embolism. Am J Respir Crit Care Med. 1998;158:65-70.
FREE FULL TEXT
58. Bates SM, Grand'Maison A, Johnston M, Naguit I, Kovacs MJ, Ginsberg JS. A latex D-dimer reliably excludes venous thromboembolism. Arch Intern Med. 2001;161:447-453.
FREE FULL TEXT
59. de Groot MR, van Marwijk Kooy M, Pouwels JG, Engelage AH, Kuipers BF, Buller HR. The use of a rapid D-dimer blood test in the diagnostic work up of
pulmonary embolism. Thromb Haemost. 1999;82:1588-1592.
ISI
| PUBMED
60. Egermayer P, Town GI, Turner JG, Heaton DC, Mee AL, Beard ME. Usefulness of D-dimer, blood gas, and respiratory rate measurements
for excluding pulmonary embolism. Thorax. 1998;53:830-834.
FREE FULL TEXT
61. Ginsberg JS, Kearon C, Douketis J, et al. The use of D-dimer testing and impedance plethysmographic examination
in patients with clinical indications of deep vein thrombosis. Arch Intern Med. 1997;157:1077-1081.
FREE FULL TEXT
62. Egermayer P, Town GI, Turner JG, Heaton DC, Mee AL, Beard ME. Usefulness of D-dimer, blood gas, and respiratory rate measurements
for excluding pulmonary embolism. Thorax. 1998;53:830-834.
63. Kline JA, Israel EG, Michelson EA, O'Neil BJ, Plewa MC, Portelli DC. Diagnostic accuracy of a bedside D-dimer assay and alveolar dead-space
measurement for rapid exclusion of pulmonary embolism. JAMA. 2001;285:761-768.
FREE FULL TEXT
64. Kollef MH, Zahid M, Eisenberg PR. Predictive value of a rapid semiquantitative D-dimer assay in critically
ill patients with suspected venous thromboembolic disease. Crit Care Med. 2000;28:414-420.
FULL TEXT
|
ISI
| PUBMED
65. Wells PS, Brill-Edwards P, Stevens P, et al. A novel and rapid whole-blood assay for D-dimer in patients with clinically
suspected deep vein thrombosis. Circulation. 1995;91:2184-2187.
FREE FULL TEXT
66. Wildberger JE, Vorwerk D, Kilbinger M, et al. Bedside testing (SimpliRED) in the diagnosis of deep vein thrombosis:
evaluation of 250 patients. Invest Radiol. 1998;33:232-235.
FULL TEXT
|
ISI
| PUBMED
67. Turkstra F, van Beek EJ, ten Cate JW, Buller HR. Reliable rapid blood test for the exclusion of venous thromboembolism
in symptomatic outpatients. Thromb Haemost. 1996;76:9-11.
ISI
| PUBMED
68. Ginsberg JS, Wells PS, Kearon C, et al. Sensitivity and specificity of a rapid whole-blood assay for D-dimer
in the diagnosis of pulmonary embolism. Ann Intern Med. 1998;129:1006-1011.
FREE FULL TEXT
69. Farrell S, Hayes T, Shaw M. A negative SimpliRED D-dimer assay result does not exclude the diagnosis
of deep vein thrombosis or pulmonary embolus in emergency department patients. Ann Emerg Med. 2000;35:121-125.
FULL TEXT
|
ISI
| PUBMED
70. Goldstein NM, Kollef MH, Ward S, Gage BF. The impact of the introduction of a rapid D-dimer assay on the diagnostic
evaluation of suspected pulmonary embolism. Arch Intern Med. 2001;161:567-571.
FREE FULL TEXT
71. Perrier A, Bounameaux H. Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. Thromb Haemost. 2001;86:475-487.
ISI
| PUBMED
72. Pieper CF, Rao KM, Currie MS, Harris TB, Cohen HJ. Age, functional status, and racial differences in plasma D-dimer levels
in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci. 2000;55:M649-M657.
73. Currie MS, Murali Krishna Rao K, Blazer DG, Cohen HJ. Age and functional correlations of markers of coagulation and inflammation
in the elderly: functional implications of elevated cross-linked fibrin degradation
products (D-dimers). J Am Geriatr Soc. 1994;42:738-742.
ISI
| PUBMED
74. Perrier A, Desmarais S, Goehring C, et al. D-dimer testing for suspected pulmonary embolism in outpatients. Am J Respir Crit Care Med. 1997;156:492-496.
FREE FULL TEXT
75. Tardy B, Tardy-Poncet B, Viallon A, et al. Evaluation of D-dimer ELISA test in elderly patients with suspected
pulmonary embolism. Thromb Haemost. 1998;79:38-41.
ISI
| PUBMED
76. Pernod G, Barro C, Satger B, et al. Positive predictive value of D-dimers in the diagnosis of pulmonary
embolism [abstract]. Thromb Haemost. 2001;86 (suppl):728.
77. Bounameaux H, de Moerloose P, Perrier A, Miron MJ. D-dimer testing in suspected venous thromboembolism: an update. Q J Med. 1997;90:437-442.
78. Sanson B, Meinders A, Kraaijenhagen A, van Beek EJ, Buller HR. Requirements for appropriate evaluation of diagnostic tests in suspected
pulmonary embolism. Haematologica. 1999;84:78-81.
79. Hull R, Hirsh J, Sackett DL, et al. Clinical validity of a negative venogram in patients with clinically
suspected venous thrombosis. Circulation. 1981;64:622-624.
FREE FULL TEXT
80. Novelline RA, Baltarowich OH, Athanasoulis CA, Waltman AC, Greenfield AJ, McKusick KA. The clinical course of patients with suspected pulmonary embolism and
a negative pulmonary arteriogram. Radiology. 1978;126:561-567.
ABSTRACT
81. Hull RD, Raskob GE, Coates G, Panju AA. Clinical validity of a normal perfusion scan in patients with suspected
pulmonary embolism. Chest. 1990;97:23-26.
FREE FULL TEXT
82. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep vein thrombosis. Lancet. 1995;345:1326-1330.
FULL TEXT
|
ISI
| PUBMED
83. Wells PS, Hirsh J, Anderson DR, et al. A simple clinical model for the diagnosis of deep vein thrombosis combined
with impedance plethysmography: potential for an improvement in the diagnostic
process. J Intern Med. 1998;243:15-23.
FULL TEXT
|
ISI
| PUBMED
84. Miron MJ, Perrier A, Bounameaux H. Clinical assessment of suspected deep vein thrombosis: comparison between
a score and empirical assessment. J Intern Med. 2000;247:249-254.
FULL TEXT
|
ISI
| PUBMED
85. Wicki J, Perneger TV, Junod AF, Bounameaux H, Perrier A. Assessing clinical probability of pulmonary embolism in the emergency
ward. Arch Intern Med. 2001;161:92-97.
FREE FULL TEXT
86. Bernardi E, Prandoni P, Lensing AW, et al. D-dimer testing as an adjunct to ultrasonography in patients with clinically
suspected deep vein thrombosis: prospective cohort study. BMJ. 1998;317:1037-1040.
FREE FULL TEXT
87. Kraaijenhagen RA, Koopman MM, Bernadi E, et al. Simplification of the diagnostic management of outpatients with symptomatic
deep vein thrombosis with D-dimer measurements [abstract]. Thromb Haemost. 1997:159.
88. Perone N, Bounameaux H, Perrier A. Comparison of four strategies for diagnosing deep vein thrombosis:
cost-effectiveness analysis. Am J Med. 2001;110:33-40.
ISI
| PUBMED
89. Perrier A, Bounameaux H, Morabia A, et al. Diagnosis of pulmonary embolism by a decision analysis–based
strategy including clinical probability, D-dimer levels and ultrasonography:
a management study. Arch Intern Med. 1996;156:531-536.
FREE FULL TEXT
90. Perrier A, Desmarais S, Miron M, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet. 1999;353:190-195.
FULL TEXT
|
ISI
| PUBMED
91. Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using
clinical assessment and D-dimer testing. Ann Intern Med. 2001;135:108-111.
FREE FULL TEXT
92. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging:
management of patients with suspected pulmonary embolism presenting to the
emergency department by using a simple clinical model and D-dimer. Ann Intern Med. 2001;135:98-107.
FREE FULL TEXT
93. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability
of pulmonary embolism: increasing the model's utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83:416-420.
ISI
| PUBMED
94. Brandstater ME, Roth EJ, Siebens HC. Venous thromboembolism in stroke: literature review and implications
for clinical practice. Arch Phys Med Rehabil. 1992;73:S379-S391.
95. Collins R, Scrigeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative
administration of subcutaneous heparin: overview of results of randomized
trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318:1162-1173.
ISI
| PUBMED
96. Siragusa S, Serafini S, Beltrametti C, Barone M, Piovella F. The incidence of post-thrombotic syndrome after asymptomatic post-operative
deep vein thrombosis: an inception cohort study [abstract]. Blood. 1998;92 (suppl 1):47a.
97. Estrada CA, McElligott J, Dolezal JM, Cunningham PR. Asymptomatic patients at high risk for deep venous thrombosis who receive
inadequate prophylaxis should be screened. South Med J. 1999;92:1145-1150.
FULL TEXT
|
ISI
| PUBMED
98. Nurmohamed NT, Rosendall FR, Buller HR, et al. Low molecular weight heparin versus standard heparin in general and
orthopaedic surgery: a meta-analysis. Lancet. 1992;340:152-155.
FULL TEXT
|
ISI
| PUBMED
99. Hull RD, Pineo GF, Francis C, et al. Low molecular weight heparin prophylaxis using dalteparin extended
out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty
patients. Arch Intern Med. 2000;160:2208-2215.
FREE FULL TEXT
100. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software, issue 1; 1999.
101. Harvey RL, Roth EJ, Yarnold PR, Durham JR, Green D. Deep vein thrombosis in stroke: the use of plasma D-dimer level as
a screening test in the rehabilitation setting. Stroke. 1996;27:1516-1520.
FREE FULL TEXT
102. Bounameaux H, Khabiri E, Huber O, et al. Value of liquid crystal contact thermography and plasma level of D-dimer
for screening of deep venous thrombosis following general abdominal surgery. Thromb Haemost. 1992;67:603-606.
ISI
| PUBMED
103. Roussi J, Bentolila S, Boudaoud L, et al. Contribution of D-dimer determination in the exclusion of deep venous
thrombosis in spinal cord injury patients. Spinal Cord. 1999;37:548-552.
FULL TEXT
|
ISI
| PUBMED
104. Crippa L, Ravasi F, D'Angelo S, et al. Diagnostic value of compression ultrasonography and fibrinogen-related
parameters for the detection of postoperative deep vein thrombosis following
elective hip replacement: a pilot study. Thromb Haemost. 1995;74:1235-1239.
ISI
| PUBMED
105. Bongard O, Wicky J, Peter R, et al. D-dimer plasma measurement in patients undergoing major hip surgery:
use in the prediction and diagnosis of postoperative proximal vein thrombosis. Thromb Res. 1994;74:487-493.
FULL TEXT
|
ISI
| PUBMED
106. Rowbotham BJ, Whitaker AN, Harrison J, Murtaugh P, Reasbeck P, Bowie EJ. Measurement of cross-linked fibrin derivatives in patients undergoing
abdominal surgery: use in the diagnosis of postoperative venous thrombosis. Blood Coagul Fibrinolysis. 1992;3:25-31.
ISI
| PUBMED
107. Lowe GD. Prediction of postoperative deep vein thrombosis. Thromb Haemost. 1997;78:47-52.
ISI
| PUBMED
108. Lowe GD, Haverkate F, Thompson SG, et al for the ECAT DVT Study Group. Prediction of deep vein thrombosis after elective hip replacement surgery
by preoperative clinical and haemostatic variables: the ECAT DVT study. Thromb Haemost. 1999;81:879-886.
ISI
| PUBMED
109. Dunn ID, Hui AC, Triffitt PD, et al. Plasma D-dimer as a marker of postoperative deep venous thrombosis:
a study after total hip or knee arthroplasty. Thromb Haemost. 1994;72:663-665.
ISI
| PUBMED
110. Douketis JD, McGinnis J, Ginsberg JS. The clinical utility of a rapid bedside D-dimer assay for screening
of deep vein thrombosis following orthopaedic surgery. Thromb Haemost. 1997;78:1300-1301.
ISI
| PUBMED
111. Kearon C, Julian JA, Math M, Newman TE, Ginsberg JS for the McMaster Diagnostic Imaging Practice Guidelines Initiative. Noninvasive diagnosis of deep venous thrombosis. Ann Intern Med. 1998;128:663-677.
FREE FULL TEXT
112. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis
of pulmonary embolism: a systematic review. Ann Intern Med. 2000;132:227-232.
FREE FULL TEXT
113. Stein PD, Hull RD, Pineo GF. The role of newer diagnostic techniques in the diagnosis of pulmonary
embolism. Curr Opin Pulm Med. 1999;5:212-215.
FULL TEXT
| PUBMED
114. Gefter WB, Hatabu H, Holland GA, Gupta KB, Henschke CI, Palevsky HI. Pulmonary thromboembolism: recent developments in diagnosis with CT
and MR imaging. Radiology. 1995;197:561-574.
FREE FULL TEXT
115. Remy-Jardin M, Remy J, Artaud D, Deschildre F, Beregi JP. Opinion response to acute pulmonary embolism: the role of computed
tomographic imaging. J Thorac Imaging. 1997;12:92-95.
116. Lorut C, Ghossains M, Horellou M, Achkar A, Fretault J, Laaban J. A noninvasive diagnostic strategy including spiral computed tomography
in patients with suspected pulmonary embolism. Am J Respir Crit Care Med. 2000;162:1413-1418.
FREE FULL TEXT
117. Ost D, Rozenshtein A, Saffran L, Snider A. The negative predictive value of spiral computed tomography for the
diagnosis of pulmonary embolism in patients with nondiagnostic ventilation-perfusion
scans. Am J Med. 2001;110:16-21.
FULL TEXT
|
ISI
| PUBMED
118. Goodman LR, Lipchik RJ, Kuzo RS, Lu Y, McAuliffe TL, O'Brien DJ. Subsequent pulmonary embolism: risk after a negative helical CT pulmonary
angiogram: prospective comparison with scintigraphy. Radiology. 2000;215:535-542.
FREE FULL TEXT
119. Polak JF, Fox LA. MR assessment of the extremity veins. Semin Ultrasound CT MR. 1999;20:36-46.
FULL TEXT
|
ISI
| PUBMED
120. Fraser DG, Moody AR, Morgan PS, Martel AL, Davidson I. Diagnosis of lower limb deep venous thrombosis (DVT): prospective blinded
study of magnetic resonance direct thrombus imaging. Ann Intern Med. 2002;136:89-98
FREE FULL TEXT
121. Moody AR, Liddicoat A, Krarup K. Magnetic resonance pulmonary angiography and direct imaging of embolus
for the detection of pulmonary emboli. Invest Radiol. 1997;32:431-440.
FULL TEXT
|
ISI
| PUBMED
122. Hull RD, Raskob GE, Ginsberg JS, et al. A non-invasive strategy for the treatment of patients with suspected
pulmonary embolism. Arch Intern Med. 1994;154:289-297.
123. Stein PD, Hull RD, Raskob GE. Withholding treatment in patients with acute pulmonary embolism who
have a high risk of bleeding and negative serial non-invasive leg tests. Am J Med. 2000;109:301-306.
FULL TEXT
|
ISI
| PUBMED
124. Dalen JE. When can treatment be withheld in patients with suspected pulmonary
embolism? Arch Intern Med. 1993;153:1415-1418.
125. ACCP Consensus Committee on Pulmonary Embolism. Opinions regarding the diagnosis and management of venous thromboembolic
disease. Chest. 1996;109:233-237.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Plasma D-Dimer Test Accuracy Can Be Affected by Heparin Administration
Sergio Siragusa
Arch Intern Med. 2003;163(2):246.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(7):847-848.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Simplification of the Revised Geneva Score for Assessing Clinical Probability of Pulmonary Embolism
Klok et al.
Arch Intern Med 2008;168:2131-2136.
ABSTRACT
| FULL TEXT
The Hidden Face of Venous Malformations: A Multidisciplinary Therapeutic Approach
Redondo
Arch Dermatol 2008;144:922-926.
FULL TEXT
Management of Suspected Acute Pulmonary Embolism in the Era of CT Angiography: A Statement from the Fleischner Society
Remy-Jardin et al.
Radiology 2007;245:315-329.
FULL TEXT
The challenges of managing cancer related venous thromboembolism in the palliative care setting
Noble
Postgrad. Med. J. 2007;83:671-674.
ABSTRACT
| FULL TEXT
D-dimers in atrial fibrillation: a further step in risk stratification of thrombo-embolism?
Cohen et al.
Eur Heart J 2007;28:2179-2180.
FULL TEXT
Evaluation of a Quantitative D-Dimer Latex Immunoassay for Acute Pulmonary Embolism Diagnosed by Computed Tomographic Angiography
Froehling et al.
Mayo Clin Proc. 2007;82:556-560.
ABSTRACT
| FULL TEXT
Diagnosis and treatment of deep-vein thrombosis.
Scarvelis and Wells
CMAJ 2006;175:1087-1092.
ABSTRACT
| FULL TEXT
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial.
Kearon et al.
ANN INTERN MED 2006;144:812-821.
ABSTRACT
| FULL TEXT
Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea.
Mueller et al.
Arch Intern Med 2006;166:1081-1087.
ABSTRACT
| FULL TEXT
Does This Patient Have Deep Vein Thrombosis?
Wells et al.
JAMA 2006;295:199-207.
ABSTRACT
| FULL TEXT
A Randomized Trial of Diagnostic Strategies after Normal Proximal Vein Ultrasonography for Suspected Deep Venous Thrombosis: D-Dimer Testing Compared with Repeated Ultrasonography
Kearon et al.
ANN INTERN MED 2005;142:490-496.
ABSTRACT
| FULL TEXT
Deferment of Objective Assessment of Deep Vein Thrombosis and Pulmonary Embolism Without Increased Risk of Thrombosis: A Practical Approach Based on the Pretest Clinical Model, D-Dimer Testing, and the Use of Low-Molecular-Weight Heparins
Siragusa et al.
Arch Intern Med 2004;164:2477-2482.
ABSTRACT
| FULL TEXT
Evaluation of the Simplify D-dimer assay as a screening test for the diagnosis of deep vein thrombosis in an emergency department
Neale et al.
Emerg. Med. J. 2004;21:663-666.
ABSTRACT
| FULL TEXT
Deep vein thrombosis: Prevalence and risk factors in rehabilitation admissions with brain injury
Yablon et al.
Neurology 2004;63:485-491.
ABSTRACT
| FULL TEXT
Diagnosis of Lower-Extremity Deep Vein Thrombosis in Outpatients
Riddle and Wells
ptjournal 2004;84:729-735.
FULL TEXT
D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis
Heim et al.
Clin. Chem. 2004;50:1136-1147.
ABSTRACT
| FULL TEXT
Diagnosing pulmonary embolism
Riedel
Postgrad. Med. J. 2004;80:309-319.
ABSTRACT
| FULL TEXT
Sensitivity and Specificity of the Semiquantitative Latex Agglutination D-Dimer Assay for the Diagnosis of Acute Pulmonary Embolism as Defined by Computed Tomographic Angiography
Froehling et al.
Mayo Clin Proc. 2004;79:164-168.
ABSTRACT
Rational Use of D-Dimer Measurement to Exclude Acute Venous Thromboembolic Disease
Frost et al.
Mayo Clin Proc. 2003;78:1385-1391.
ABSTRACT
The Evaluation of Suspected Pulmonary Embolism
Fedullo and Tapson
NEJM 2003;349:1247-1256.
FULL TEXT
D-Dimer Levels and Risk of Recurrent Venous Thromboembolism
Eichinger et al.
JAMA 2003;290:1071-1074.
ABSTRACT
| FULL TEXT
Managing pulmonary embolism
Janata
BMJ 2003;326:1341-1342.
FULL TEXT
Diagnosis, investigation, and management of deep vein thrombosis
Tovey and Wyatt
BMJ 2003;326:1180-1184.
FULL TEXT
A Diagnostic Strategy Involving a Quantitative Latex D-Dimer Assay Reliably Excludes Deep Venous Thrombosis
Bates et al.
ANN INTERN MED 2003;138:787-794.
ABSTRACT
| FULL TEXT
Plasma D-Dimer Test Accuracy Can Be Affected by Heparin Administration
Siragusa
Arch Intern Med 2003;163:246-246.
FULL TEXT
Potency of Inhaled Corticosteroid Fails to Predict Reduced Emergency Department Visits
Williams
Arch Intern Med 2003;163:247-248.
FULL TEXT
|
